Humanized anti-CD134 (OX40) antibodies and uses thereof
US10273307B2 · kind B2 · utility
3Cited by
26References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 11, 2017 |
| Grant date | Apr 30, 2019 |
| Priority date | — |
| Expiry date | Sep 11, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.